Seth Klarman: portfolio of Baupost Group

Seth Klarman leads the Baupost Group, which follows a value approach and looks for securities trading below their estimated worth.

Source: 13F filing with the US Securities and Exchange Commission dated Nov 13, 2017. It shows positions at quarter end and is filed up to 45 days later – today the positions may be several months old. It covers only securities traded on US exchanges, without short positions; securities traded only abroad and cash are not included.

You are looking at Q3 2017. Go to the latest filing (Q3 2026)

8.0B USDQ3 2017
Total value of stock positions
8.0B USD
Positions
36
Share of the ten largest
78.5%

The ten largest positions Q3 2017

  1. Cheniere Energy Inc 11.7%unchanged
  2. Synchrony Financial 11.4%unchanged
  3. Viasat Inc 10.6%unchanged
  4. Qorvo Inc 8.0%unchanged
  5. Allergan PLC 7.6%▲ +21.9%
  6. Colony Northstar Inc 7.5%unchanged
  7. Twenty First Centy Fox Inc 6.3%unchanged
  8. Antero Res Corp 6.0%▲ +12.9%
  9. Pbf Energy Inc 5.4%unchanged
  10. Theravance Biopharma Inc 4.0%▲ +0.4%
Total value of stock positions per quarter, Q2 2013 to Q3 2026 (peak 12.7B USD).
Choose a quarter (54 filings)

All positions Q3 2017

Positions Q3 2017 per 13F filing, 36 of 36
Symbol Weight Shares Reported value Change Held since
Viasat Inc 10.6% 13,158,137 846.3M USD unchanged Q2 2013 or earlier 18 quarters
Novagold Res Inc 0.5% 9,500,000 39.1M USD unchanged Q2 2013 or earlier 18 quarters
Pbf Energy Inc 5.4% 15,724,175 434.1M USD unchanged Q3 2013 17 quarters
Cheniere Energy Inc 11.7% 20,726,340 933.5M USD unchanged Q1 2014 15 quarters
Keryx Biopharmaceuticals Inc 2.3% 25,791,678 183.1M USD unchanged Q1 2014 15 quarters
Theravance Biopharma Inc 4.0% 9,309,168 318.7M USD +0.4% increased Q2 2014 14 quarters
Antero Res Corp 6.0% 23,912,257 475.9M USD +12.9% increased Q3 2014 13 quarters
Veritiv Corp 1.2% 3,053,724 99.2M USD +0.3% increased Q3 2014 13 quarters
Atara Biotherapeutics Inc 1.1% 5,359,632 88.7M USD unchanged Q4 2014 12 quarters
Paratek Pharmaceuticals Inc 0.8% 2,394,498 60.1M USD unchanged Q4 2014 12 quarters
Forward Pharma A/S 0.5% 6,463,265 39.2M USD +1.6% increased Q4 2014 12 quarters
Twenty First Centy Fox Inc 6.3% 19,137,469 504.8M USD unchanged Q3 2015 9 quarters
Twenty First Centy Fox Inc 2.4% 7,384,542 190.4M USD +1.5% increased Q3 2015 9 quarters
RUN Sunrun 0.2% 2,848,082 15.8M USD unchanged Q3 2015 9 quarters
Allergan PLC 7.6% 2,964,203 607.5M USD +21.9% increased Q1 2016 7 quarters
SYF Synchrony Financial 11.4% 29,295,030 909.6M USD unchanged Q3 2016 5 quarters
DELL Dell Technologies 3.0% 3,052,459 235.7M USD −46.0% reduced Q3 2016 5 quarters
Trilogy Metals Inc New 0.1% 10,600,758 10.0M USD unchanged Q3 2016 5 quarters
Orexigen Therapeutics Inc < 0.1% 2,226,839 4.7M USD unchanged Q3 2016 5 quarters
CAH Cardinal Health 2.1% 2,530,000 169.3M USD +24.6% increased Q4 2016 4 quarters
Chipmos Technologies Inc 0.7% 3,048,295 58.9M USD −13.2% reduced Q4 2016 4 quarters
Gty Technology Holdings Inc 0.6% 4,400,000 46.0M USD unchanged Q4 2016 4 quarters
Centennial Resource Dev Inc 0.5% 2,407,153 42.1M USD unchanged Q4 2016 4 quarters
Cascadian Therapeutics Inc 0.4% 8,721,079 35.7M USD unchanged Q4 2016 4 quarters
Saban Cap Acquisition Corp 0.3% 2,326,500 23.4M USD unchanged Q4 2016 4 quarters
Saban Cap Acquisition Corp < 0.1% 1,163,250 1.4M USD unchanged Q4 2016 4 quarters
Qorvo Inc 8.0% 9,000,000 636.1M USD unchanged Q1 2017 3 quarters
Colony Northstar Inc 7.5% 47,905,461 601.7M USD unchanged Q1 2017 3 quarters
Express Scripts Hldg Co 2.0% 2,556,891 161.9M USD unchanged Q1 2017 3 quarters
Avis Budget Group 0.5% 1,036,900 39.5M USD −74.1% reduced Q2 2017 2 quarters
Silver Run Acquisition 0.3% 2,149,352 21.9M USD −67.5% reduced Q2 2017 2 quarters
MCK McKesson Corporation 1.0% 500,000 76.8M USD new Q3 2017 1 quarter
AMC AMC Entertainment 0.7% 3,565,361 52.4M USD new Q3 2017 1 quarter
COR Cencora 0.2% 188,850 15.6M USD new Q3 2017 1 quarter
Pioneer Nat Res Co < 0.1% 28,895 4.3M USD new Q3 2017 1 quarter
Simply Good Foods Co < 0.1% 1,035,146 2.5M USD new Q3 2017 1 quarter

“Held since”: the first quarter from which the position appears in the 13F filing at every quarter end. It first appears at the end of that quarter – the filing gives neither date nor price, and trading between two quarter ends is not visible. “Or earlier”: the position was already in the first available filing (or the first one after a gap in filings). After a change of the security identifier (e.g. a renaming) the start may appear later.

Plus 1 position in convertible bonds and bonds worth 37.1M USD as reported – not included in the weights.

Convertible bonds and bonds, principal amount as reported. They are not stock positions and therefore do not count towards the weights.

  • Theravance Biopharma Inc principal 30.0M USD 37.1M USD

Breakdown by sector

  • Financials 11.4%
  • Health Care 3.3%
  • Technology 3.0%
  • Communication Services 0.7%
  • Industrials 0.2%
  • not in our coverage 81.5%

Sectors only for stocks we cover; the rest is grouped under “not in our coverage”.

How to read this page

  • Weight: a position’s share of the total value of all reported stock positions in this quarter – options and bonds are not counted.
  • Change: number of shares compared with the previous quarter. After a stock split we convert the previous quarter’s share count so that a split does not look like an increase; if a possible split cannot be confirmed, “–” is shown.
  • Reported value: value of the position at quarter end as reported by the investor. The portfolio may have changed since then.

All superinvestor portfolios Screener: stocks held by superinvestors

↑ ↓ select · Enter open · Esc close